CardioVere

10/13/2022

With the potential to provide physicians with more accurate data to advance the standard of care, the results of CardioVere’s latest clinical study show a promising future that could empower providers and heart failure patients to screen, manage, and monitor at all points of care.

When compared to MRI in evaluating lower extremity tissue congestion measurement, our patented Molecular Chemical Imaging (MCI) technology performed with great results!

You can take a closer look at the full study here: https://bit.ly/3SUy4Ng

10/05/2022

Looking back at a great meeting this past weekend at . The team enjoyed connecting with the best in heart failure management!

The highlight of the weekend was our clinical study “Non-Contact Molecular Chemical Imaging for Evaluation of Congestion: A Validation Study Compared to MRI” being presented by Dr. Peter Eckman of the Minneapolis Heart Institute Foundation. Thank you to Dr. Eckman and the rest of the CardioVere Team for an insightful presentation! Visit our website to have a look at the study poster: https://bit.ly/3SFuvKJ

10/02/2022

We are proud to present the results of our latest clinical study showing the potential of CardioVere technology as a measurement tool for tissue congestion in heart failure patients as compared to MRI. This study is a tremendous advancement forward for CardioVere. We congratulate our physicians, scientists, and professionals who contributed. Please have a look at the results here: https://bit.ly/3SMgTgw

09/30/2022

The team is at this weekend! We are honored to have been selected by Heart Failure Society of America - HFSA to present our clinical study results tomorrow in the ePoster hub. If you are at the meeting, please join us Saturday at 6:15pm as we share exciting and ground-breaking results that have the potential to advance heart failure care and management.

09/29/2022

According to the CDC, 1 in 5 Americans will develop Heart Failure (HF) in their lifetime. Today on , we bring awareness to Cardiovascular Disease (CVD) and the need for better heart failure management. At CardioVere, it is our mission to provide clinicians with precise information earlier to improve HF patient care.

How? We’re working to advance the standard of care with breakthrough, patented Molecular Chemical Imaging (MCI) technology that can empower providers and HF patients to screen, manage, and monitor the disease at all points-of-care. CardioVere has the potential to help detect HF earlier, reduce readmissions, and improve patient outcomes.

Learn more about CardioVere technology now at https://bit.ly/3DWryB4

09/27/2022

We can't wait for this week where we will unveil the results of our clinical study comparing our patented Molecular Chemical Imaging (MCI) technology against MRI when evaluating lower extremity congestion.

Until then, we’re pleased to give you a detailed look at the design of the study in our infographic here: https://bit.ly/3CaKJ8X

09/17/2022

CardioVere is proud to celebrate World Patient Safety Day 2022! With our breakthrough solution intended to precisely and objectively measure tissue congestion in heart failure patients, CardioVere has the potential to provide physicians with more accurate data, advancing the standard of care for heart failure patients.

Established by the World Health Organization (WHO), World Patient Safety Day gives us the opportunity to recognize the importance of patient safety and discover new ways to care for patients. Visit our website to learn more about our technology and how it could contribute to a safer patient experience. Visit: https://bit.ly/3ROg4n3

09/08/2022

According to Heart Failure Society of America - HFSA, the prevalence of heart failure is expected to increase from 6.5 million Americans to >8 million by 2030. CardioVere is designed to be the next generation congestion measurement device to help manage heart failure patients using our patented Molecular Chemical Imaging (MCI) technology.

Join us at where we will unveil our latest clinical study results comparing our CardioVere technology to the traditional MRI method. We look forward to being among the best of heart failure science, research, and practical management and hope you can join us for our poster presentation.

08/11/2022

CardioVere is proud to announce our abstract has been selected for poster presentation at the Heart Failure Society of America - HFSA 2022 Annual Scientific Meeting in Washington, DC on Sept. 30th.

Our poster will feature results of our clinical study comparing our patented Molecular Chemical Imaging (MCI) technology against the gold standard, MRI, when evaluating lower extremity congestion, establishing an important basis for CardioVere’s continued development as the potential next generation of tissue congestion measurement to help screen, monitor, and manage heart failure patients.

We are thrilled to be recognized by the Heart Failure Society of America for our work and hope you can join us to hear the results! Visit https://bit.ly/3AdIfW9 to read the full press release and to learn more about our technology.

02/04/2022

American Heart month is underway and today we celebrate Go Red For Women National Wear Red Day®, designed to increase women’s heart health awareness. About 435,000 women have heart attacks in the U.S. yearly. Symptoms can be so mild they’re dismissed as something minor. Learn the important warning signs: https://bit.ly/32Wt71E. ChemImage Corporation understands the impact of cardiac health and is leveraging our patented technology to develop advancements in precision medicine, learn more: https://bit.ly/3rsehtq

Learn more about the warning signs of heart attack and stroke in women that may differ from those men experience.

12/01/2021

We are excited to welcome Carl Denys to the ChemImage team! As a seasoned executive who thrives on leading teams and promoting customer-focused cultures, Carl joins us as Vice President, Medical Devices. He will focus on identifying expansion opportunities for the company’s patented technology in medical applications. To read the full press release, click here: https://bit.ly/31nnZ5t

Advanced Imaging and Machine Learning Company Taps Medical Device Executive to Lead Expansion in Medical Applications for Patented Technology ChemImage, a leader in advanced imaging and machine learning technology, has recruited Carl Denys to its executive management team. Mr. Denys will report to P...

11/10/2021

Did you know that more than 6 million Americans are living with heart failure? ChemImage Corporation is developing ways to help heart failure patients and assist clinicians in assessment and monitoring with the use of CardioVere. Check out our latest blog post, “Advances in Home Monitoring of Heart Failure Patients.” https://bit.ly/3wAIes1 American Heart Association SPIE, the international society for optics and photonics

ChemImage is also exploring and developing ways to help heart failure patients and assist clinicians in assessment and monitoring by developing a non-invasive early indicator of acute HF decompensation called CardioVere.